334 related articles for article (PubMed ID: 22408046)
1. Mosquirix (RTS,S): a novel vaccine for the prevention of Plasmodium falciparum malaria.
Wilby KJ; Lau TT; Gilchrist SE; Ensom MH
Ann Pharmacother; 2012 Mar; 46(3):384-93. PubMed ID: 22408046
[TBL] [Abstract][Full Text] [Related]
2. Duration of vaccine efficacy against malaria: 5th year of follow-up in children vaccinated with RTS,S/AS02 in Mozambique.
Campo JJ; Sacarlal J; Aponte JJ; Aide P; Nhabomba AJ; Dobaño C; Alonso PL
Vaccine; 2014 Apr; 32(19):2209-16. PubMed ID: 24631081
[TBL] [Abstract][Full Text] [Related]
3. [The malaria vaccine candidate RTS,S/AS is in phase III clinical trials].
Cohen J; Benns S; Vekemans J; Leach A
Ann Pharm Fr; 2010 Nov; 68(6):370-9. PubMed ID: 21073995
[TBL] [Abstract][Full Text] [Related]
4. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial.
Alonso PL; Sacarlal J; Aponte JJ; Leach A; Macete E; Aide P; Sigauque B; Milman J; Mandomando I; Bassat Q; Guinovart C; Espasa M; Corachan S; Lievens M; Navia MM; Dubois MC; Menendez C; Dubovsky F; Cohen J; Thompson R; Ballou WR
Lancet; 2005 Dec; 366(9502):2012-8. PubMed ID: 16338450
[TBL] [Abstract][Full Text] [Related]
5. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection.
Kester KE; Cummings JF; Ofori-Anyinam O; Ockenhouse CF; Krzych U; Moris P; Schwenk R; Nielsen RA; Debebe Z; Pinelis E; Juompan L; Williams J; Dowler M; Stewart VA; Wirtz RA; Dubois MC; Lievens M; Cohen J; Ballou WR; Heppner DG;
J Infect Dis; 2009 Aug; 200(3):337-46. PubMed ID: 19569965
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants.
Abdulla S; Oberholzer R; Juma O; Kubhoja S; Machera F; Membi C; Omari S; Urassa A; Mshinda H; Jumanne A; Salim N; Shomari M; Aebi T; Schellenberg DM; Carter T; Villafana T; Demoitié MA; Dubois MC; Leach A; Lievens M; Vekemans J; Cohen J; Ballou WR; Tanner M
N Engl J Med; 2008 Dec; 359(24):2533-44. PubMed ID: 19064623
[TBL] [Abstract][Full Text] [Related]
7. Safety of the RTS,S/AS02A malaria vaccine in Mozambican children during a Phase IIb trial.
Sacarlal J; Aponte JJ; Aide P; Mandomando I; Bassat Q; Guinovart C; Leach A; Milman J; Macete E; Espasa M; Ofori-Anyinam O; Thonnard J; Corachan S; Dubois MC; Lievens M; Dubovsky F; Ballou WR; Cohen J; Alonso PL
Vaccine; 2008 Jan; 26(2):174-84. PubMed ID: 18069097
[TBL] [Abstract][Full Text] [Related]
8. Development of the RTS,S/AS malaria candidate vaccine.
Vekemans J; Leach A; Cohen J
Vaccine; 2009 Dec; 27 Suppl 6():G67-71. PubMed ID: 20006143
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicty of RTS,S/AS02A candidate malaria vaccine in Gambian children.
Bojang KA; Olodude F; Pinder M; Ofori-Anyinam O; Vigneron L; Fitzpatrick S; Njie F; Kassanga A; Leach A; Milman J; Rabinovich R; McAdam KP; Kester KE; Heppner DG; Cohen JD; Tornieporth N; Milligan PJ
Vaccine; 2005 Jul; 23(32):4148-57. PubMed ID: 15964483
[TBL] [Abstract][Full Text] [Related]
10. RTS,S/AS02A for malaria.
Bojang KA
Expert Rev Vaccines; 2006 Oct; 5(5):611-5. PubMed ID: 17181435
[TBL] [Abstract][Full Text] [Related]
11. Long-term safety and efficacy of the RTS,S/AS02A malaria vaccine in Mozambican children.
Sacarlal J; Aide P; Aponte JJ; Renom M; Leach A; Mandomando I; Lievens M; Bassat Q; Lafuente S; Macete E; Vekemans J; Guinovart C; Sigaúque B; Sillman M; Milman J; Dubois MC; Demoitié MA; Thonnard J; Menéndez C; Ballou WR; Cohen J; Alonso PL
J Infect Dis; 2009 Aug; 200(3):329-36. PubMed ID: 19569964
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial.
Alonso PL; Sacarlal J; Aponte JJ; Leach A; Macete E; Milman J; Mandomando I; Spiessens B; Guinovart C; Espasa M; Bassat Q; Aide P; Ofori-Anyinam O; Navia MM; Corachan S; Ceuppens M; Dubois MC; Demoitié MA; Dubovsky F; Menéndez C; Tornieporth N; Ballou WR; Thompson R; Cohen J
Lancet; 2004 Oct 16-22; 364(9443):1411-20. PubMed ID: 15488216
[TBL] [Abstract][Full Text] [Related]
13. Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research.
Heppner DG; Kester KE; Ockenhouse CF; Tornieporth N; Ofori O; Lyon JA; Stewart VA; Dubois P; Lanar DE; Krzych U; Moris P; Angov E; Cummings JF; Leach A; Hall BT; Dutta S; Schwenk R; Hillier C; Barbosa A; Ware LA; Nair L; Darko CA; Withers MR; Ogutu B; Polhemus ME; Fukuda M; Pichyangkul S; Gettyacamin M; Diggs C; Soisson L; Milman J; Dubois MC; Garçon N; Tucker K; Wittes J; Plowe CV; Thera MA; Duombo OK; Pau MG; Goudsmit J; Ballou WR; Cohen J
Vaccine; 2005 Mar; 23(17-18):2243-50. PubMed ID: 15755604
[TBL] [Abstract][Full Text] [Related]
14. Four year immunogenicity of the RTS,S/AS02(A) malaria vaccine in Mozambican children during a phase IIb trial.
Aide P; Dobaño C; Sacarlal J; Aponte JJ; Mandomando I; Guinovart C; Bassat Q; Renom M; Puyol L; Macete E; Herreros E; Leach A; Dubois MC; Demoitie MA; Lievens M; Vekemans J; Loucq C; Ballou WR; Cohen J; Alonso PL
Vaccine; 2011 Aug; 29(35):6059-67. PubMed ID: 21443960
[TBL] [Abstract][Full Text] [Related]
15. Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial.
Aponte JJ; Aide P; Renom M; Mandomando I; Bassat Q; Sacarlal J; Manaca MN; Lafuente S; Barbosa A; Leach A; Lievens M; Vekemans J; Sigauque B; Dubois MC; Demoitié MA; Sillman M; Savarese B; McNeil JG; Macete E; Ballou WR; Cohen J; Alonso PL
Lancet; 2007 Nov; 370(9598):1543-51. PubMed ID: 17949807
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of the RTS,S/AS02A candidate malaria vaccine in children aged 1-4 in Mozambique.
Macete E; Aponte JJ; Guinovart C; Sacarlal J; Ofori-Anyinam O; Mandomando I; Espasa M; Bevilacqua C; Leach A; Dubois MC; Heppner DG; Tello L; Milman J; Cohen J; Dubovsky F; Tornieporth N; Thompson R; Alonso PL
Trop Med Int Health; 2007 Jan; 12(1):37-46. PubMed ID: 17207146
[TBL] [Abstract][Full Text] [Related]
17. The Plasmodium sporozoite survives RTS,S vaccination.
Snounou G; Grüner AC; Müller-Graf CD; Mazier D; Rénia L
Trends Parasitol; 2005 Oct; 21(10):456-61. PubMed ID: 16109504
[TBL] [Abstract][Full Text] [Related]
18. Pooled analysis of safety data from pediatric Phase II RTS,S/AS malaria candidate vaccine trials.
Vekemans J; Guerra Y; Lievens M; Benns S; Lapierre D; Leach A; Verstraeten T
Hum Vaccin; 2011 Dec; 7(12):1309-16. PubMed ID: 22108035
[TBL] [Abstract][Full Text] [Related]
19. Heterologous prime-boost immunization in rhesus macaques by two, optimally spaced particle-mediated epidermal deliveries of Plasmodium falciparum circumsporozoite protein-encoding DNA, followed by intramuscular RTS,S/AS02A.
Walsh DS; Gettayacamin M; Leitner WW; Lyon JA; Stewart VA; Marit G; Pichyangkul S; Gosi P; Tongtawe P; Kester KE; Holland CA; Kolodny N; Cohen J; Voss G; Ballou WR; Heppner DG
Vaccine; 2006 May; 24(19):4167-78. PubMed ID: 16574282
[TBL] [Abstract][Full Text] [Related]
20. Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A.
Stewart VA; McGrath SM; Walsh DS; Davis S; Hess AS; Ware LA; Kester KE; Cummings JF; Burge JR; Voss G; Delchambre M; Garçon N; Tang DB; Cohen JD; Heppner DG
Vaccine; 2006 Oct; 24(42-43):6483-92. PubMed ID: 16904798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
